A contract research organization (CRO), Medpace runs the full span of clinical drug trials — from early safety tests to post-market studies — for small and mid-sized biopharma companies, including medical oversight, monitoring, labs, and regulatory work. Founded in Cincinnati in 1992 by Dr. August Troendle, a former FDA reviewer, it was originally called Medical Research Services; the name Medpace blends "medical" with "pace," reflecting its mission to speed trials along. It also built its own software, ClinTrak, to track studies in real time, and keeps its central labs and a Phase I unit on its own Cincinnati campus.
Medpace stockholders approve charter amendments removing supermajority and special meeting limits.
At the May 15, 2026 Annual Meeting, stockholders approved amendments to remove supermajority voting requirements and the limitation on calling special meetings.
Show detailsHide details
The charter amendments became effective May 18, 2026 upon filing with the Delaware Secretary of State, along with a restated certificate of incorporation.
The Board adopted Bylaw Amendments allowing stockholders owning at least 25% of voting power for one year to call special meetings.
All five director nominees were elected, and Deloitte & Touche LLP was ratified as independent auditor for fiscal year 2026.
Stockholders approved, on an advisory basis, executive compensation and an annual frequency for future advisory votes.
5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · 5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits
Medpace President Jesse Geiger to retire May 31, 2026; CEO reassumes President role
The departure is not due to any disagreement with the Company regarding operations, policies, or practices.
Show detailsHide details
Jesse Geiger notified Medpace on April 21, 2026 of his resignation as President, effective May 31, 2026.
CEO August Troendle will reassume the role of President effective on Geiger's resignation date until a successor is appointed.
Medpace also reported Q1 2026 revenue of $706.6 million, up 26.5% year-over-year, and GAAP net income of $123.9 million ($4.28 per diluted share).
2.02 Results of Operations and Financial Condition · 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 9.01 Financial Statements and Exhibits
Medpace reports Q3 2025 revenue of $659.9M, up 23.7% year-over-year
Revenue for Q3 2025 was $659.9 million, a 23.7% increase from $533.3 million in Q3 2024.
Show detailsHide details
GAAP net income for Q3 2025 was $111.1 million, or $3.86 per diluted share, versus $96.4 million, or $3.01 per diluted share, in the prior-year period.
Net new business awards were $789.6 million in Q3 2025, up 47.9% from $533.7 million a year ago, with a net book-to-bill ratio of 1.20x.
EBITDA for Q3 2025 was $148.4 million, up 24.9% from $118.8 million in Q3 2024, with an EBITDA margin of 22.5%.
The company forecasts 2025 revenue of $2.480 billion to $2.530 billion and GAAP diluted EPS of $14.60 to $14.86.
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
Medpace stockholders approve 2016 Amended and Restated Incentive Award Plan at 2025 Annual Meeting
August J. Troendle and Dani S. Zander were elected as Class III directors to serve until the 2026 Annual Meeting.
Show detailsHide details
At the May 16, 2025 Annual Meeting, stockholders approved the 2016 Amended and Restated Incentive Award Plan, which extends the expiration date to February 6, 2035 without increasing authorized shares.
Stockholders ratified Deloitte & Touche LLP as independent auditor for fiscal year 2025.
The advisory say-on-pay proposal for named executive officer compensation was approved.
A non-binding stockholder proposal on simple majority voting was approved.
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits